A Phase II Clinical Trial to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients
Latest Information Update: 07 Feb 2023
At a glance
- Drugs Entecavir (Primary) ; T 101 (Primary) ; Tenofovir (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Sponsors Transgene Tasly (Tianjin) BioPharmaceutical
Most Recent Events
- 05 Feb 2021 Planned primary completion date changed from 1 Dec 2020 to 30 Jun 2021.
- 06 Dec 2020 Status changed from recruiting to active, no longer recruiting.
- 13 Dec 2019 Status changed from not yet recruiting to recruiting.